In addition to being a core early event in OSCC, abnormal STAT3 activation represents a potential risk factor for poor prognosis in early-stage patients (106, 124) and in later disease stages correlates with poor tumor differentiation, lymph node metastasis and reduced survival (16, 106). Here, STAT3 is linked to neoplasm.